Previous studies demonstrated that the ORR was 45% in lung cancer patients with PD-L1 TPS ≥ 50% receiving pembrolizumab monotherapy [3,4], which was comparable to the ORR of 61.4% in unselected lung cancer patients receiving a combination of pembrolizumab and chemotherapy [5]. The gene discussed is CD274; the disease is lung carcinoma.